Table 2.
Base-case results for five DDP-4 treatment strategies.
| Outcomes | Linagliptin | Alogliptin | Saxagliptin | Sitagliptin | Vildagliptin |
|---|---|---|---|---|---|
| Events | |||||
| MI | 9.63% | 9.61% | 9.65% | 9.64% | 9.67% |
| Stroke | 22.06% | 22.00% | 22.13% | 22.10% | 22.19% |
| CHF | 15.68% | 15.65% | 15.71% | 15.69% | 15.74% |
| ASCVD | 15.44% | 15.42% | 15.46% | 15.45% | 15.49% |
| CVD death | 22.41% | 22.36% | 22.46% | 22.44% | 22.51% |
| ESRD | 4.14% | 4.13% | 4.15% | 4.14% | 4.15% |
| Blindness | 4.13% | 4.13% | 4.13% | 4.13% | 4.13% |
| Clinical neuropathy | 14.69% | 14.69% | 14.69% | 14.69% | 14.69% |
| Minor amputation | 11.43% | 11.43% | 11.43% | 11.43% | 11.43% |
| Major amputation | 8.43% | 8.43% | 8.43% | 8.43% | 8.43% |
| Total QALY | 10.412 | 10.419 | 10.405 | 10.408 | 10.397 |
| Total LY | 20.852 | 20.866 | 20.837 | 20.844 | 20.822 |
| Total Cost (US $) | 13,821 | 13,828 | 13,786 | 13,735 | 13,866 |
| ICER (US $/QALY)* | Extended dominated | 6,952 | Dominated | NA | Dominated |
*Compared with the sitagliptin strategy because it is the cheapest strategy. NA, not applicable.